Panbio Pharm Llc

Panbio Pharm LLC is a Russian pharmaceutical importer and distributor specializing in the procurement and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2019, the company is headquartered in Reutov, Moscow Region, Russia. The legal address is 143960, Moscow Region, Reutov, Fabrichnaya Street, Building 8A, Room 14. (pbf.health) Panbio Pharm LLC plays a significant role in Russia's pharmaceutical supply chain by sourcing a diverse range of pharmaceutical products from international suppliers, particularly from India, to meet the domestic market's needs.

Panbio Pharm LLC operates a centralized distribution network with its primary warehouse located in Reutov, Moscow Region. This strategic location enables efficient logistics and distribution across Russia. The company has expanded its operations to include local production facilities, with plans to commence the production of painkillers and joint disease treatments in Reutov, enhancing its supply chain resilience and reducing dependency on imports.

In Russia's pharmaceutical supply chain, Panbio Pharm LLC functions as a primary wholesaler and distributor. The company imports finished pharmaceutical formulations from international suppliers, particularly from India, and distributes these products to various stakeholders, including retail pharmacies, hospitals, and healthcare providers across Russia. By sourcing a wide array of pharmaceutical products, Panbio Pharm LLC ensures a steady supply of essential medications to meet the diverse needs of the Russian healthcare system.

Panbio Pharm LLC demonstrates a high degree of supplier concentration, with 75% of its imports sourced from Panacea Biotec Pharma Limited, 16.7% from Simpex Pharma Private Limited, and 8.3% from Micro Labs Limited. This concentration indicates a strategic choice to establish strong partnerships with select suppliers, potentially ensuring consistent product quality and favorable terms. However, such dependency also poses risks, including supply chain disruptions if any of these suppliers face operational challenges. The company's decision to diversify its supplier base by including multiple suppliers from India suggests a proactive approach to mitigating these risks.

Panbio Pharm LLC's supply chain resilience is bolstered by its diversified sourcing strategy, engaging multiple suppliers from India. The company's plan to initiate local production in Reutov further enhances its supply chain stability by reducing reliance on international suppliers and mitigating potential disruptions. Additionally, the implementation of a customized CRM system developed by Sber Business Soft in June 2023 indicates a commitment to optimizing operations and improving responsiveness to market demands. (akm.ru)

The sourcing pattern of Panbio Pharm LLC, characterized by strong partnerships with select Indian suppliers and plans for local production, positions the company to maintain a competitive edge in the Russian pharmaceutical market. For Indian exporters, this presents an opportunity to strengthen existing relationships and explore new avenues for collaboration, particularly in supplying high-demand pharmaceutical products that align with Panbio Pharm LLC's portfolio.

In Russia, the Federal Service for Surveillance in Healthcare (Roszdravnadzor) is the primary regulatory authority overseeing pharmaceutical imports and ensuring compliance with national standards. Key legislation governing pharmaceutical imports includes the Federal Law No. 61-FZ "On Circulation of Medicines," which outlines the requirements for importing, registering, and distributing pharmaceutical products in Russia. The marketing authorization pathway for Indian generics involves obtaining a Certificate of Pharmaceutical Product (COPP) from the exporting country, followed by registration with Roszdravnadzor, which includes submission of technical documentation, clinical trial data, and compliance with Good Manufacturing Practice (GMP) standards.

Import licensing requirements for pharmaceutical products in Russia necessitate that foreign manufacturers hold valid GMP certificates recognized by Roszdravnadzor. These certificates must be issued by competent authorities in the exporting country and demonstrate compliance with international GMP standards. Indian exporters seeking to supply Panbio Pharm LLC must ensure that their manufacturing facilities are GMP-compliant and that they possess the necessary certifications to facilitate the import process into Russia.

Pharmaceutical products imported into Russia must undergo batch testing to verify quality and safety. Stability studies are required to ensure that products maintain their efficacy and safety throughout their shelf life. Labeling must be in Russian, including detailed information on the product's composition, dosage, usage instructions, and storage conditions. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, Russia has implemented several regulatory changes affecting pharmaceutical imports. These include stricter requirements for GMP certification, enhanced scrutiny of clinical trial data, and more rigorous labeling and packaging standards to improve patient safety and product traceability. Indian pharmaceutical exporters must stay abreast of these changes to ensure compliance and maintain uninterrupted access to the Russian market.

Panbio Pharm LLC's focus on importing nutritional supplements, vitamins, and respiratory OTC products aligns with the growing demand for preventive healthcare and wellness products in Russia. The company's portfolio strategy addresses prevalent health concerns, such as joint diseases and respiratory conditions, by sourcing products that offer therapeutic benefits and cater to the health-conscious consumer segment.

Panbio Pharm LLC's sourcing strategy emphasizes the procurement of generic drugs, particularly those with established efficacy and safety profiles. The company's preference for formulations that are well-suited to the Russian market, including those with appropriate dosage forms and packaging, reflects a strategic approach to meeting local consumer needs. India's robust pharmaceutical manufacturing capabilities and adherence to international quality standards make it a preferred sourcing partner for Panbio Pharm LLC.

Based on its product mix, Panbio Pharm LLC serves multiple segments of the Russian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's diverse portfolio enables it to cater to a wide range of healthcare providers and consumers, positioning it as a versatile and reliable distributor in the Russian market.

There is a realistic opportunity for new Indian suppliers to collaborate with Panbio Pharm LLC, particularly in supplying high-demand pharmaceutical products that align with the company's therapeutic focus areas. Gaps in Panbio Pharm LLC's current sourcing may exist in specialized formulations or emerging therapeutic areas, presenting opportunities for Indian exporters to introduce innovative products to the Russian market.

Indian exporters seeking to supply Panbio Pharm LLC and the Russian market must possess valid GMP certifications recognized by Roszdravnadzor, such as WHO-GMP or EU-GMP. They must also provide comprehensive technical documentation, including COPP, Certificate of Analysis (COA), stability data, batch records, and product formulas, to facilitate the import and registration process in Russia.

To establish a relationship with Panbio Pharm LLC, Indian exporters should initiate contact through formal channels, presenting their product portfolios and demonstrating compliance with Russian regulatory requirements. Participating in industry trade fairs and conferences in Russia can also provide opportunities for direct engagement. Developing a clear regulatory filing strategy, including the preparation of necessary documentation and understanding of the registration process, is essential. Timelines for regulatory approval can vary; therefore, maintaining open communication with Panbio Pharm LLC and Russian regulatory authorities is crucial to ensure a smooth market entry.